mesalamine has been researched along with Intestinal Neoplasms in 8 studies
Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.
Intestinal Neoplasms: Tumors or cancer of the INTESTINES.
Excerpt | Relevance | Reference |
---|---|---|
"The relative risk of colorectal cancer in ulcerative colitis is increased, however, there're marked geographically differences." | 2.43 | [Inflammatory bowel disease and colorectal cancer]. ( Hagymási, K; Tulassay, Z, 2006) |
"The medical records of patients with Crohn's disease (CD) and ulcerative colitis (UC) diagnosed with IBD-associated intestinal neoplasia (dysplasia or cancer) from 1983 to 2020 were included in this study." | 1.91 | Effect of Biologics on the Risk of Advanced-Stage Inflammatory Bowel Disease-Associated Intestinal Cancer: A Nationwide Study. ( Ajioka, Y; Akagi, Y; Arakaki, J; Daito, K; Futami, K; Goi, T; Hanai, T; Hasegawa, J; Hida, K; Ikeuchi, H; Iseki, Y; Ishida, F; Ishihara, S; Itabashi, M; Kanemitsu, Y; Katsumata, K; Kazama, S; Kimura, H; Kinugasa, Y; Kiyomatsu, T; Komori, K; Koyama, F; Maeda, K; Maemoto, A; Matsuda, K; Nakamura, M; Nezu, R; Noake, T; Noguchi, T; Ogino, T; Ohge, H; Okabayashi, K; Okamoto, K; Okuda, J; Sasaki, S; Sato, Y; Seishima, R; Shida, D; Sugihara, K; Sunami, E; Suto, T; Takahashi, K; Toiyama, Y; Uchino, M; Uehara, K; Ueno, H; Wakai, T; Watanabe, K; Yamada, K; Yamada, T; Yamaguchi, S; Yamamoto, S; Yamamoto, T, 2023) |
"No significant risk for other intestinal cancers was found, especially for small bowel carcinoma." | 1.43 | Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study. ( Charpentier, C; Cheddani, H; Dauchet, L; Dupas, JL; Fumery, M; Gower-Rousseau, C; Marie Bouvier, A; Pariente, B; Peyrin-Biroulet, L; Savoye, G, 2016) |
"Data from all patients with Crohn's disease whose diagnosis had been performed before 1st January 1978 were analyzed." | 1.32 | Crohn's disease over 20 years after diagnosis in a referral population. ( Beaugerie, L; Bouhnik, Y; Cosnes, J; Etienney, I; Gendre, JP; Lémann, M; Matuchansky, C; Modigliani, R; Rambaud, JC, 2004) |
" To directly evaluate the ability of 5-ASA to suppress intestinal tumors, we studied several formulations of 5-ASA (free acid, sulfasalazine, and Pentasa) at multiple oral dosage levels [500, 2400, 4800, and 9600 parts/million (ppm)] in the adenomatous polyposis coli (Apc) mouse model of multiple intestinal neoplasia (Min)." | 1.30 | Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse. ( Gendler, SJ; Hirsch, RE; Leighton, JA; Morrow, JD; Ritland, SR; Weaver, AL, 1999) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (25.00) | 18.2507 |
2000's | 3 (37.50) | 29.6817 |
2010's | 2 (25.00) | 24.3611 |
2020's | 1 (12.50) | 2.80 |
Authors | Studies |
---|---|
Seishima, R | 1 |
Okabayashi, K | 1 |
Ikeuchi, H | 1 |
Uchino, M | 1 |
Futami, K | 1 |
Noguchi, T | 1 |
Ohge, H | 1 |
Iseki, Y | 1 |
Watanabe, K | 1 |
Itabashi, M | 1 |
Okamoto, K | 1 |
Toiyama, Y | 1 |
Ogino, T | 1 |
Nakamura, M | 1 |
Yamada, K | 1 |
Wakai, T | 1 |
Sato, Y | 1 |
Kimura, H | 1 |
Takahashi, K | 1 |
Hida, K | 1 |
Kinugasa, Y | 1 |
Ishida, F | 1 |
Okuda, J | 1 |
Daito, K | 1 |
Koyama, F | 1 |
Ueno, H | 1 |
Yamamoto, T | 1 |
Yamamoto, S | 1 |
Hanai, T | 1 |
Maemoto, A | 1 |
Arakaki, J | 1 |
Komori, K | 1 |
Akagi, Y | 1 |
Shida, D | 1 |
Yamaguchi, S | 1 |
Matsuda, K | 1 |
Maeda, K | 1 |
Noake, T | 1 |
Nezu, R | 1 |
Sasaki, S | 1 |
Hasegawa, J | 1 |
Sunami, E | 1 |
Kanemitsu, Y | 1 |
Katsumata, K | 1 |
Uehara, K | 1 |
Kiyomatsu, T | 1 |
Suto, T | 1 |
Kazama, S | 1 |
Yamada, T | 1 |
Goi, T | 1 |
Ishihara, S | 1 |
Ajioka, Y | 1 |
Sugihara, K | 1 |
Dammann, K | 1 |
Khare, V | 1 |
Harpain, F | 1 |
Lang, M | 1 |
Kurtovic, A | 1 |
Mesteri, I | 1 |
Evstatiev, R | 1 |
Gasche, C | 1 |
Cheddani, H | 1 |
Dauchet, L | 1 |
Fumery, M | 1 |
Charpentier, C | 1 |
Marie Bouvier, A | 1 |
Dupas, JL | 1 |
Pariente, B | 1 |
Peyrin-Biroulet, L | 1 |
Savoye, G | 1 |
Gower-Rousseau, C | 1 |
Etienney, I | 1 |
Bouhnik, Y | 1 |
Gendre, JP | 1 |
Lémann, M | 1 |
Cosnes, J | 1 |
Matuchansky, C | 1 |
Beaugerie, L | 1 |
Modigliani, R | 1 |
Rambaud, JC | 1 |
Hagymási, K | 1 |
Tulassay, Z | 1 |
Veldman, W | 1 |
van Beek, M | 1 |
Keuning, JJ | 1 |
Driessen, WM | 1 |
Ritland, SR | 1 |
Leighton, JA | 1 |
Hirsch, RE | 1 |
Morrow, JD | 1 |
Weaver, AL | 1 |
Gendler, SJ | 1 |
MacGregor, DJ | 1 |
Kim, YS | 1 |
Sleisenger, MH | 1 |
Johnson, LK | 1 |
1 review available for mesalamine and Intestinal Neoplasms
Article | Year |
---|---|
[Inflammatory bowel disease and colorectal cancer].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cholangitis, Sclerosing; Colitis, Ulcerative; Colonoscopy; | 2006 |
7 other studies available for mesalamine and Intestinal Neoplasms
Article | Year |
---|---|
Effect of Biologics on the Risk of Advanced-Stage Inflammatory Bowel Disease-Associated Intestinal Cancer: A Nationwide Study.
Topics: Biological Products; Colitis, Ulcerative; Crohn Disease; Humans; Immunologic Factors; Inflammatory B | 2023 |
PAK1 promotes intestinal tumor initiation.
Topics: Animals; Azoxymethane; beta Catenin; Carcinogenesis; Colonoscopy; Dextrans; Female; Gene Deletion; G | 2015 |
Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.
Topics: Adrenal Cortex Hormones; Age of Onset; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroi | 2016 |
Crohn's disease over 20 years after diagnosis in a referral population.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Az | 2004 |
Regional enteritis complicating malignant lymphoma.
Topics: Adult; Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti | 1996 |
Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse.
Topics: Adenomatous Polyps; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Chemo | 1999 |
Chemoprevention of colon cancer carcinogenesis by balsalazide: inhibition of azoxymethane-induced aberrant crypt formation in the rat colon and intestinal tumor formation in the B6-Min/+ mouse.
Topics: Aminosalicylic Acids; Animals; Anti-Ulcer Agents; Anticarcinogenic Agents; Azoxymethane; Cell Divisi | 2000 |